Kymriah To Set Off Alarms As it Becomes Japan’s Most Expensive Drug?
Executive Summary
Novartis CAR-T therapy becomes most expensive drug ever covered by Japan’s national health insurance system. Although authorities expect total sales to be modest, might high price again raise official concerns over ballooning health costs?
You may also be interested in...
Japan Cell, Regenerative Therapy Environment ‘Exciting’ But Ongoing Dialog Needed
While the environment for cell and regenerative medicines in Japan is ‘exciting’ and positive, ongoing dialog with policy makers and regulators is needed to ensure a reflection of industry and patient concerns, one CEO says.
Cell Therapies Forge Ahead In Japan with Reimbursement, Approval Decisions
A controversial cell therapy for spinal injuries receives coverage under Japan’s national health scheme, amid signs that the pricing of regenerative therapies may come under more scrutiny, while the first CAR-T treatment in the country takes a step closer to market.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.